Stelara is one of the most successful Crohn’s therapies, generating $10.8bn last year, Lilly hopes to introduce Omvoh as its ...

At 52 weeks of follow-up, more patients on Eli Lilly’s monoclonal antibody Omvoh demonstrated histologic response, suggesting ...

On a mission to collect a key Crohn’s disease approval and build out its inflammatory bowel disease (IBD) profile, Eli Lilly ...

The stock of Eli Lilly and Company LLY has declined 1.7% already this week, losing almost $14 billion of its market value.

礼来公司米瑞木单抗在克罗恩病治疗中的有望结果与公司强劲的财务表现和市场地位相一致。根据InvestingPro数据,礼来公司拥有8,392.5亿美元的巨大市值,反映了投资者对其增长潜力和创新管线的信心。

2024年，制药行业迎来了机遇与挑战并存的复杂局面。近期的科学突破不断带来新的治疗方案，但政府法规、飙升的成本、沉重的患者负担，以及全球紧张局势等因素抑制了投资者的热情。基于以上背景，AdisInsight推出了一份专题报告《突破性疗法与重磅药物：新 ...

Results from the national "Urgent Conversations" survey, announced today by Eli Lilly and Company (NYSE: LLY), found that ...

Lilly announces positive results from phase 3 study of mirikizumab compared to ustekinumab for Crohn's disease: Indianapolis Tuesday, October 15, 2024, 18:00 Hrs [IST] Eli Lilly a ...

Spherix Global Insights said AbbVie’s Skyrizi has quickly blasted past Eli Lilly’s Omvoh in ulcerative colitis, ...

On Monday, Eli Lilly And Co (NYSE:LLY) announced data from a VIVID-1 Phase 3 study that evaluated the safety and efficacy of ...

J&J beat expectations this week to launch the Q3 earnings season; a study about children treated with bluebird bio’s Skysona ...

Eli Lilly and Company (NYSE: LLY) announced data demonstrating more patients with moderately to severely active Crohn's ...